Dermata Therapeutics, Inc. (DRMAW) Financials

DRMAW Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 7.5 million 1.1 million
Dec. 31, 2025 7.9 million 1.6 million
Sept. 30, 2025 5.1 million 1.1 million
June 30, 2025 6.6 million 1.0 million

DRMAW Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -2.5 million 43278
Dec. 31, 2025 -1.3 million 29469
Sept. 30, 2025 -1.8 million 37841
June 30, 2025 -2.7 million 39233

DRMAW Net Income

No data available :(

DRMAW Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 6.9 million - -
Dec. 31, 2025 7.5 million - -
Sept. 30, 2025 4.7 million - -
June 30, 2025 6.5 million - -

DRMAW Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 3.9 million
Dec. 31, 2025 1.2 million
Sept. 30, 2025 1.0 million
June 30, 2025 1.0 million

DRMAW Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 383724 1.5 million -
Dec. 31, 2025 3 526620 1.4 million -
Sept. 30, 2025 5 504387 1.3 million 472940
June 30, 2025 - 617835 1.2 million -

DRMAW Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -

DRMAW

Price: $0.01

52 week price:
0.01
0.02

Earnings Per Share: -2.16 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 203

Market Capitalization: 9337

Links: